The Market Fieldbook

Confirming your account

Your account is being prepared. You will be redirected securely in a moment.

The Market Fieldbook

Company Observatory

A

Agilent Technologies, Inc.

Healthcare · Medical - Diagnostics & Research

Overall research band Mixed
Quality Mixed
Valuation Mixed
Balance sheet Mixed
Market confirmation Strong

One-minute company read

What this report can tell you now

What the company does

Agilent Technologies, Inc. delivers specialized technologies and services to the global life sciences, diagnostics, and applied chemistry industries. Its main products include analytical instrumentation such as liquid and gas chromatography systems, mass spectrometry, atomic absorption, and spectroscopy tools, as well as cell analysis solutions like flow cytometers and microplate readers. The Diagnostics and Genomics division provides genetic research tools, including DNA arrays, target enrichment for sequencing, custom oligonucleotides, and specialized staining solutions. Agilent CrossLab offers laboratory consumables, instrument supplies, and a range of support services such as training, compliance, and asset management. The company serves its customers through direct sales, distributors, resellers, manufacturer's representatives, and e-commerce, generating revenue from product sales and laboratory services.

The current research profile is Mixed Setup, with strong market confirmation. This is a starting point for investigation, not a forecast or recommendation.

Strongest visible signal

Recent market behavior is the strongest visible confirmation. Check whether it agrees with the underlying business evidence.

What to investigate next

Read the latest filing or company update, check the period behind the metrics, and investigate the dimension with the weakest band above.

Before you draw a conclusion

  • Read the latest filing or company update.
  • Check the financial period behind each metric.
  • Investigate the weakest score band and any missing evidence.

Headline fundamentals

A small set of signals worth checking

ROIC16.3%Model input; read with the evidence status and period context.
Operating margin21.3%Model input; read with the evidence status and period context.
Revenue CAGR · 4 years2.4%Model input; read with the evidence status and period context.
FCF margin16.6%Model input; read with the evidence status and period context.

Go deeper when you need to

Compare the right companies, understand what changed, and monitor the evidence.

Peer contextCompare companies using the appropriate economic neighborhood.
Evidence detailSee exact inputs, source context, and model-aware metrics.
HistoryReview score and research changes over time.
MonitoringKeep the questions, risks, and changes that matter in view.

The public report remains useful on its own. Premium adds depth, history, comparison, and monitoring.